A share price of Neurocrine Biosciences, Inc [NBIX] is currently trading at $100.10, up 4.10%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NBIX shares have gain 5.06% over the last week, with a monthly amount drifted -8.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurocrine Biosciences, Inc [NASDAQ: NBIX] stock has seen the most recent analyst activity on April 15, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $138 for it. Previously, RBC Capital Mkts upgraded its rating to Outperform on April 14, 2025, and kept the price target unchanged to $137. On February 11, 2025, Deutsche Bank initiated with a Hold rating and assigned a price target of $138 on the stock. Piper Sandler upgraded its rating to a Overweight and raised its price target to $159 on August 29, 2024. Wells Fargo upgraded its rating to Overweight for this stock on April 24, 2024, and upped its price target to $170.
Neurocrine Biosciences, Inc experienced fluctuations in its stock price throughout the past year between $84.23 and $157.98. Currently, Wall Street analysts expect the stock to reach $156.25 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $100.10 at the most recent close of the market. An investor can expect a potential return of 56.09% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Trailing Twelve Months sales for Neurocrine Biosciences, Inc [NASDAQ:NBIX] were 2.36B which represents 21.84% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.25%, Pretax Profit Margin comes in at 0.21%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.13 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 98.05 points at the first support level, and at 96.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 101.40, and for the 2nd resistance point, it is at 102.71.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neurocrine Biosciences, Inc [NASDAQ:NBIX] is 3.40. Also, the Quick Ratio is 3.28, while the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 4.20, the price to book ratio is 3.84 and price to earnings (TTM) ratio is 30.42.
Transactions by insiders
Recent insider trading involved Cooke Julie, Chief Human Resources Officer, that happened on Feb 13 ’25 when 1551.0 shares were sold. Director, GORMAN KEVIN CHARLES completed a deal on Feb 13 ’25 to sell 5844.0 shares. Meanwhile, Director SHERWIN STEPHEN A sold 13831.0 shares on Feb 13 ’25.
